Early Access — free while we kick the tires
EdgarHawk

Watanabe Todd

See Remarks

Director Officer
3 filings analyzed · 1 company · Latest 2025-11-24

Companies

Company Buys Sells Direction
Arcutis Biotherapeutics, Inc. ARQT 2 3 Net selling

Activity

November 2025
high
Sell
50,000 shares
$1,517,405
Significance 7/10

Arcutis CFO Todd Watanabe sells 50,000 shares ($1.5M) across two transactions near 52-week high; mixed signal after strong 90-day rally of +94.3%

Watanabe sold 50,000 shares (50.0K shares) totaling $1,517,404.84 at a blended average price of $30.35, reducing his stake from 790.5K to 740.5K shares. The sales occurred as ARQT stock reached its 52-week high of $30.76, following a sharp 90-day rally of +94.3% and 30-day surge of +53.0%. While Watanabe's prior trades at ARQT showed consistent 90-day success (3 of 3 prior trades well-timed), his cross-ticker track record shows strong execution (100% win rate, avg 90d return +226.6%), so the timing signal here is ambiguous—the stock is at a valuation peak, but the company is now profitable on a quarterly basis with revenue of $99.2M and net income of $7.4M, having posted +229.7% annual revenue growth. The sale size represents 6.3% of pre-transaction holdings and occurs against a backdrop where the 52-week range is $10.09–$30.76, meaning current levels are neither distressed nor cheap. Investors should note this reflects a near-full-cycle liquidity event at an extreme valuation point, distinct from a conviction signal in either direction.

October 2025
high
Sell
40,000 shares
$1,001,032
Significance 7/10

Watanabe Todd sold 40,000 shares of ARQT at $25.03 on 2025-10-28 (total $1.0M); stock has gained 32.2% in 30d, 74.4% in 90d from prior lows.

Watanabe Todd sold 40,000 shares (4.7% of his pre-transaction holdings) at $25.03, near the 52-week high of $25.29, as ARQT has surged 32.2% over the past 30 days and 74.4% over 90 days. His prior three purchases at ARQT all delivered substantial positive 90-day returns (up 49.4%, 92.6%, and 550.1%), establishing a pattern of well-timed entry points at this ticker. This sale occurs after an exceptional run-up from depressed levels ($8.31 52-week low) and comes as the company achieved profitability in the latest quarter ($7.4M net income) despite being unprofitable on a full-year basis, with annual revenue growth of 229.7%. The sale reduces his position from 846.4K to 806.4K shares while maintaining significant holdings, signaling a tactical reduction after substantial appreciation rather than a full exit.

December 2024
high
Buy
6,038 shares
$21,250
Significance 7/10

Watanabe Franklin buys 6,038 shares at blended $3.52 across 2 transactions; cluster pattern with 2 other insiders buying within 14 days

Watanabe Franklin executed 2 separate purchases totaling 6,038 shares for $21,250.03 at a blended average price of $3.52, raising his holdings from 832,392 to 838,430 shares. The stock currently trades at $12.27, up 41.5% over 30 days and 17.3% over 90 days from the transaction dates. His prior open-market buy at ARQT on 2023-05-31 also preceded gains (30d +49.4%, 90d +37.0%), establishing a pattern of well-timed entry points at this ticker. Critically, this filing is part of a cluster in which 2 other insiders also bought within the past 14 days, suggesting coordinated confidence among the management team despite the company's current unprofitability (net income $-41.5M) and reliance on revenue momentum (FY growth of +1517.1%).

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access